Form 4 for ADIL ADIAL PHARMACEUTICALS, INC.
Accepted 2023-01-03 00:00:00 ET · period of report 2022-12-30 · accession 0001213900-23-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-03 | 2022-12-30 | ADIL | Stilley William B. III | Dir | D - Sale to Iss | $0.00 | -166.7K | 1.02M | -14% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-30 | D | D | 166,667 | $0.00 | 1,020,979 | D | — | — | (F1) Represents the cancellation of 166,667 previously outstanding shares of restricted common stock of Adial Pharmaceuticals, Inc. originally issued on February 23, 2022. |